


IMMUNO-ONCOLOGY SOCIETY OF INDIA

2nd I-OSI Annual Congress 2020





I-OSI Virtual Congress



Organizing Secretary

Dr. Jyoti Bajpai, MD, DM Founder General Secretary, I-OSI Professor, Medical Oncology, Tata Memorial Centre, Mumbai

For free entry to watch conference put your name, email id and mobile no. on the below link

www.immunooncologyindia.com/iosi

Participants will get 4 CME credit points



Dear Friends,

My greetings and well wishes to all of you for your good health and inspiring work in cancer and community care.

On behalf of the Immuno-oncology Society of India(I-OSI), I am pleased to welcome you for the 2nd Annual National Congress to be held as a three days virtual programme on October 30th to 31st (4 PM - 9 PM India Standard Time) and Nov 1st, 2020 (9 AM - 1.30 PM IST).

This conference will assess the current state of immuno-oncology that highlights for cancer care professionals the current research, utilization trends, and coming advances for immunotherapies. Hence, the theme of this year's conference is **"Immuno-Oncology towards 2021: Reboot, Resolve and Evolve"**.

The huge learning curve that immuno-oncology presented has significantly flattened out just by virtue of the explosive availability of immuno-oncology therapies in cancer care. In many cases, it has become the standard of care, and if you want to practice oncology today, you have to keep yourself abreast with the new tricks. The IOSICON 2020 therefore aims to meet these needs of multidisciplinary care teams and describes next steps for supporting optimal delivery of immunotherapies.

With 3876 agents and 469 targets in 2019 the recent white paper points to the likelihood of further expansion of immunotherapy to treat more patients in the future. Factors that support this belief include the emergence of checkpoint inhibitors as feasible therapies in a variety of adjuvant and neoadjuvant settings, an increase in utilization of immuno-oncology therapies as part of combination regimens or in sequence with chemotherapy or targeted agents, and the increase of immuno-oncology delivery in the community setting.

Additionally, I-OSICON will also try to address survivorship needs, which includes unpredictable and delayed immune-related adverse events, follow-up, and psychosocial support.

For over 2 years, I-OSI has been the leader in promoting tumor immunology and advancing cancer immunotherapy education, information and research in India. As the paradigm in cancer treatment changes, I-OSI Annual Meeting continues to lead and drive the numerous advances our field is making.

We have various sponsorship opportunities for pharma partners and we request you to get in touch with our event manager and discuss the same.

Looking forward to your whole hearted support.

Regards,

Dr. Jyoti Bajpai, Organizing Secretary, I-OSI 2020 **Founder General Secretary:** Immuno-Oncology Society of India (I-OSI) Professor, Medical Oncology, Tata Memorial Centre, Mumbai, India

Click on below link to watch conference

www.immunooncologyindia.com/iosi

- EDUCATIONAL PARTNER



- ENDORSEMENTS









CONFERENCE COMMITTEE			
Patrons	Dr. R. A. Badwe		
	Dr. S. H. Advani		
	Dr. Asha Kapadia		
Organising Chairpersons	Dr. Shubhada Chiplunkar		
	Dr. S. D. Banavali		
	Dr. Hemant Malhotra		
Organising Secretary	Dr. Jyoti Bajpai		
Joint Organising Secretaries	Dr. Vivek Radhakrishnan		
	Dr. Rahul Purwar		
Scientific Committee Chair	Dr. Atul Sharma		
	Dr. Kumar Prabhash		
	Dr. (Surg Cdr) Gaurav Narula		
Advisory Committee	Dr. B. K.Smruti		
	Dr. Vikram Mathews		
	Dr. Reena Nair		
	Dr. Moni Abraham Kuriakose		
	Dr. Rakesh Jalali		
	Dr. Senthil Rajappa		
	Dr. Girdhari Lal		
	Dr. Amit Awasthi		



INVITED INTERNATIONAL FACULTY



Dr. James P. Allison Nobel Laureate for Physiology and Medicine Regental Professor & Chair, Department of Immunology, Olga Keith Wiess Distinguished University Chair for Cancer Research, Director, Parker Institute for Cancer Research, Executive Director, Immunotherapy Platform, MD Anderson Cancer Center, USA



Dr. Jedd D. Wolchok

Chief, Immuno-Oncology Service, Human Oncology and Pathogenesis Program Lloyd J. Old Chair, Clinical Investigation, Director, Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering, Associate Director, Ludwig Center for Cancer Immunotherapy, Professor of Medicine, Weill Medical College of Cornell University, USA



Dr. Rakesh K. Jain Ph.D., A. W. Cook Professor of Radiation Oncology (Tumor Biology), Director, E.L. Steele Laboratories Department of Radiation Oncology Harvard Medical School and Massachusetts General Hospital Boston, USA



Dr. Solange Peters Head of the Medical Oncology Department, Head of the Specialized Consultation for Thoracic Tumors, Physician in charge of the Center for thoracic tumors University of Lausanne, Switzerland



Dr. John B. Haanen Head of the Division of Medical Oncology and Staff Scientist, Division of Immunology, Professor of Translational Immunotherapy of Cancer, Leiden University Medical Centre, The Netherlands



INVITED INTERNATIONAL FACULTY



Dr. Olivera J. Finn Chair and Professor, Department of Immunology, University of Pittsburgh School of Medicine, Director of the Immunology Program, University of Pittsburgh Cancer Institute, USA



Dr. Padmanee Sharma Professor, Department of Genitourinary Medical Oncology, Professor,Department of immune-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Cente

The University of Texas MD Anderson Cancer Center, USA



Dr. Sherene Loi MMBS (Hons), FRACP, PhD, FAHMS Professor, Cancer Therapeutics Head, Translational Breast Cancer Genomics and Therapeutics Lab, Peter MacCallum Cancer Centre University of Melbourne, Melbourne, Australia



Prof. Silvia Stacchiotti Department of Medical Oncology IRCCS Foundation,National Cancer Institute, Milan, Italy



Dr. David Gottlieb Professor of Haematology University of Sydney Program Director BMT, Head Cell Therapies, Westmead Hospital Sydney, Sydney



Prof. Laura Locati Head and Neck Unit Depart of Medical Oncology IRCCS Foundation, National Cancer Institute, Milan, Italy



INVITED INTERNATIONAL FACULTY



Dr. Ravindran Kanesvaran Deputy Head & Senior Consultant, Division of Medical Oncology, National Cancer Centre, Singapore



Dr. Aung Naing Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, USA



Dr. Naval G. Daver Associate Professor, Department of Leukemia, MD Anderson Cancer Center, USA



Dr. Aditi Shastri Assistant Professor of Oncology, Division of Hematologic Malignancies & Bone Marrow Transplant, Montefiore Medical Center & Albert Einstein College of Medicine, Bronx, New York, USA



Dr. Nirali N. Shah M.D., M.H.Sc. Investigator, Pediatric Oncology Branch, NIH Lasker Clinical Research Scholar, NIH Distinguished Scholar Head, Hematologic Malignancies Section, Center for Cancer Research, National Cancer Institute USA



Dr. Boro Dropulic Chief Science Officer Lentigen Technology, Inc. USA



LIVES I-OSI Virtual Congress

SCIE	NTIFIC PROGRAM FRIDAY 30 TH OCTOBER, DAY 1
15:30 - 16:10	Conference Inauguration Dr. R. A. Badwe, Dr. Shubhada Chiplunkar, Dr. Jyoti Bajpai, Dr. Sudeep Gupta, Dr. S. D. Banavali, Dr. C. S. Pramesh Dr. Hemant Malhotra, Dr. Kumar Prabhash
	Announcement for "Sprinkles Cancer Care Foundation"
	🏤 Chairpersons : Dr. Anil D'Cruz, Dr. Sadashivudu Gundeti
	Session Italy Time:- 11:40 - 12:20
16:10 - 16:15	Session introduction
16:15 - 16:40	Immunotherapy in Head and Neck cancers : Investing in knowledge paying the best dividends Speaker : Dr. Laura Locati
16:40 - 16:50	🕫 Q & A
	Lead Discussant : Dr. Vanita Noronha
	🏦 Chairpersons : Dr. Rajiv Sarin, Dr. Vinay Deshmane
	Session Australia Time:- 22:20 - 23:00
16:50 - 16:55	Session introduction
16:55 - 17:20	Immunotherapy of Breast cancers : Facts can beat anything you fancy Speaker : Dr. Sherene Loi
17:20 - 17:30	🗫 Q & A
	Lead Discussant : Dr. Sudeep Gupta
	🏤 Chairpersons : Dr. Asha Kapadia, Dr. Jaya Ghosh
	Session USA Time:- 07:00 - 07:40
17:30 - 17:35	Session introduction
17:35 - 18:00	Strategies for improving management of immune related adverse events Speaker : Dr. Aung Naing
18:00 - 18:10	Q & A Lead Discussant : Dr. Sewanti Limaye
	🏤 Chairpersons : Dr. D. C. Doval, Dr. Vinod Raina
	Session Netherlands Time:- 13:40 - 14:20
18:10 - 18:15	Session introduction



LIVES I-OSI Virtual Congress

SCIEN	NTIFIC PROGRAM FRIDAY 30 TH OCTOBER, DAY 1
18:15 - 18:40	Mitigating checkpoint inhibitors toxicities Speaker: Dr. John B. Haanen
18:40 - 18:50	Q & A Lead Discussant : Dr. Atul Sharma
	🏔 Chairpersons : Dr. Shubhada Chiplunkar, Dr. Girdhari Lal
	Session USA Time:- 09:20 - 10:00
18:50 - 18:55	Session introduction
18:55 - 19:20	Vaccines for the prevention of human non-viral cancers Speaker : Dr. Olivera J. Finn
19:20 - 19:30	Q & A Lead Discussant : Dr. Shyam Aggarwal
	Chairpersons : Dr. Avnish Saklani, Dr. Vineet Talwar, Dr. S. D. Banavali
	Session USA:- 10:00 -11:00
19:30 - 19:35	Session introduction
19:35 - 20:20	 Oration - Checkpoint Blockade Therapy : Focusing on Combinations to Improve Outcomes Speaker : Dr. Jedd Wolchok
20:20 - 20:30	Q & A Lead Discussant : Dr. T. Raja
	Chairpersons : Dr. Ramesh Nimmagadda, Dr. Padmaj Kulkarni
	Italy Time:- 16:00 - 16:45
20:30 - 21:15	 Panel discussion : Check point inhibitors in solid tumors: Practical applications of guidelines in Indian context Moderator : Dr. Senthil Rajappa Panelist : Dr. Laura Locati, Dr. B. K. Smruti, Dr. Amit Rauthan, Dr. T.P. Sahoo, Dr. Ullas Batra, Dr. Amit Joshi, Dr. Shona Nag, Dr. Bhawna Sirohi, Dr. Amit Agarwal
21:15 - 21:20	Important announcements



LIVES I-OSI Virtual Congress

SCIENT	IFIC PROGRAM SATURDAY 31 st OCTOBER, DAY 2		
	🏝 Chairpersons : Dr. C.S. Pramesh, Dr. J.P. Agarwal		
	Session Switzerland Time:- 12:40 - 13:20		
16:10 - 16:15	Session introduction		
16:15 - 16:40	Breakthroughs in Lung Cancer Immunotherapy :		
	The Story of Fiction in Medicine Speaker : Dr. Solange Peters		
16:40 - 16:50			
10.40 10.00	Lead Discussant : Dr. Navneet Singh		
	🏔 Chairpersons : Dr. Siddharth Laskar, Dr. Bharat Rekhi		
	Session Italy Time:- 12:20 - 13:00		
16:50 - 16:55	Session introduction		
16:55 - 17:20	Immunotherapy of Sarcoma : Amusing the patients		
	or / and Curing the disease		
17:20 - 17:30	Speaker : Prof. Silvia Stacchiotti		
17.20 - 17.30	Q & A Lead Discussant : Dr. Chirag Desai		
	🏔 Chairpersons : Dr. Raghunadarao D., Dr. Jyoti Wadhwa		
	Session Singapore Time:- 20:00 - 20:40		
17:30 - 17:35	Session introduction		
17:35 - 18:00	Immunotherapy in rare and challenging situations		
	(Extreme of ages, comorbidities, immunocompromised and autoimmune conditions)		
	Speaker : Dr. Ravindran Kanesvaran		
18:00 - 18:10	🕫 Q & A		
	Lead Discussant: Dr. G.S. Bhattacharya		
	Chairpersons : Dr. Moni Abraham Kuriakose, Dr. Navin Khattry		
	Session USA Time:- 07:40 - 08:20		
18:10 - 18:15	Session introduction		
18:15 - 18:40	From the Clinic to the Lab : Evaluating Mechanisms of Response and Resistance to Immune Checkpoint Therapy		
	Speaker : Dr. Padmanee Sharma		



LIVES I-OSI Virtual Congress

SCIENT	IFIC	PROGRAM SATURDAY 31 st OCTOBER, DAY 2
18:40 - 18:50	Ç.	Q & A
		Lead Discussant : Dr. Nitesh Rohatgi
	*	Chairpersons : Dr. Amit Awasthi, Dr. Dipankar Nandi
		Session USA Time:- 09:20 - 10:00
18:50 - 18:55	*	Session introduction
18:55 - 19:20		Normalizing the tumor microenvironment to improve immunotherapy of cancer : Bench to Bedside Speaker : Dr. Rakesh K. Jain
19:20 - 19:30	ŝĊ	Q & A
		Lead Discussant : Dr. S.D. Banavali
	*	Chairpersons : Dr. Sudeep Gupta, Dr. Govind Babu, Dr. Jyoti Bajpai
		Session USA Time:- 09:00 - 10:00
19:30 - 19:35	*	Session introduction
19:35 - 20:20		Oration - Immune Checkpoint Blockade in Cancer Therapy : New insights into therapeutic mechanisms Speaker : Dr. James P. Allison
20:20 - 20:30	Ç;	Q & A
		Lead Discussant : Dr. Kumar Prabhash
	*	Chairpersons : Dr. S.H. Advani, Dr. Bhavna Parikh
		Singapore Time:- 23:00 - 23:45
		Italy time:- 16:00 - 16:45 Switzerland time:- 17:00 - 17:45
		USA time:- 10:00 - 10:45
20:30 - 21:15		Panel discussion : Optimal management of Rare
		Diseases & Situations in clinics
		Moderator : Dr. Jyoti BajpaiPanelist :Dr. Silvia Stacchiotti, Dr. Solange Peters, Dr. Ravindran Kanesvaran, Dr. Aung Naing, Ms. Nishu Goel, Dr. Rakesh Jalali, Dr. Bharath Rangarajan, Dr. Amish Vora
21:15 - 21:20		Important announcements



LIVE I-OSI Virtual Congress

SCIEN	TIFIC PROGRAM SUNDAY 1 ST NOVEMBER, DAY 3
	🏔 Chairpersons : Dr. Maheboob Basade, Dr. Vikram Mathews
	Session USA Time:- 23:30 - 00:10
09:00 - 09:05	Session introduction
09:05 - 09:30	Nuances in Automated and Decentralized CAR-T Cell Manufacture Speaker : Dr. Boro Dropulic
09:30 - 09:40	Q & A Lead Discussant : Dr. Chetan Dhamne
	🎝 Chairpersons : Dr. Anita Ramesh, Dr. Reetu Jain
	Session USA Time:- 23:10 - 23:50
09:40 - 09:45	Session introduction
09:45 - 10:10	Immunotherapy (Antibodies (ADCs and BiTEs), checkpoint inhibitors, CD47) in hematological malignancies Speaker: Dr. Naval G. Daver
10:10 - 10:20	Q & A Lead Discussant : Dr. Hemant Malhotra
	🏝 Chairpersons: Dr. Purna Kurkure, Dr. Pankaj Malhotra
	Session USA Time:- 00:50 - 01:30
10:20 - 10:25	Session introduction
10:25 - 10:50	CAR-T Cells : Beyond CD19 Speaker : Dr. Nirali Shah
10:50 - 11:00	♀ Q & A Lead Discussant : Dr. (Surg Cdr) Gaurav Narula
11:00 - 11:25	Session USA Time:- 01:30 - 02:20 CAR-T cell therapy in rare and challenging situations (Extreme of ages, comorbidities, CNS disease) Speaker : Dr. Aditi Shastri



LIVES I-OSI Virtual Congress

SCIEN	TIFIC PROGRAM SUNDAY 1 st NOVEMBER, DAY 3	
	Chairpersons: Dr. Purvish Parikh, Dr. Sunil Arora	
11:25 - 11:30	Session Introduction	
11:30 - 11.45	CAR-T cell therapy : Indian context Speaker : Dr. Rahul Purwar	
11:45 - 11:55	Q & A Lead Discussant : Dr. Vivek Radhakrishnan	
	🎎 Chairpersons : Dr. Tapan Saikia, Dr. Lalit Kumar	
	Session Sydney Time:- 17:25 - 18:05	
11:55 - 12:00	Session introduction	
12:00 - 12:25	Applications of adoptive immunotherapy following intensive therapy in oncology Speaker: Dr. David Gottlieb	
12:25 - 12:35	Q & A Lead Discussant : Prashant Mehta	
	🏶 Chairpersons : Dr. Prakash Chitalkar, Dr. Soumen Basak	
12:35 - 13:15	 Panel discussion : Immunotherapy in haematolymphoid malignancies - Its potential and future promise Moderator : Dr. Manju Sengar Pannelist : Dr. Ashish Bakshi, Dr. Rahul Purwar, Dr. Hari Menon, Dr. Sameer Bakhshi, Dr. Hasmukh Jain, Dr. Vipul Sheth, Dr. Abhay Bhave, Dr. Lingaraj Nayak 	
13:15 - 13:25	Indian Data Presentation National Centres : Dr. George Abraham	
13:25 – 13:35	Vote of thanks : Organizing Committee	

Click on below link to watch conference

www.immunooncologyindia.com/iosi


ACADEMIC PARTNERS : GOLD SPONSORS



Bristol Myers Squibb



The first anti–PDL1 immunotherapy for multiple cancer types ——



OS ADVANTAGE OF ATEZOLIZUMAB IN PHASE III STUDIES OF NSCLC, ES-SCLC, UC AND TNBC

	Study, Therapy line (Therapy Arm)	Population	HR (95 % Cl)	HR (95 % Cl)	Median OS, Months A-Arm ControlArm
NSCLC	IMpower150 ¹ , 1L (A + Bev + Carbo + P vs. Bev + Carbo + P)	ITT-WT ь (N = 696)		0.78 ^a (0.64–0.96)	19.2 14.7
	OAK ² , 2L (A mono vs. Doc)	ITT (N = 850)	⊢ , I	0.73 (0.62–0.87)	13.8 9.6
ES-SCLC	IMpower133³, 1L (A + Carbo + E vs. Plac + Carbo + E)	(N = 403)		0.70 (0.54–0.91)	12.3 10.3
\	IMvigor211 ⁴ , 2L (A mono vs. Vin/P/Doc)	III (N = 931)	 -++-1 	0.85 ^a (0.73–0.99)	8.6 8.0
	IMpassion130⁵, 1L (A + nab-P vs. Plac + nab-P)	PD-L1 IC+ (N = 369)	·•	0.71 ^{a, b} (0.54–0.93)	25.0 [§] 18.0

0,3 Advantage A-Arm - 1 - Advantage Control -Arm

\$ The IMpassion130 study did not reach the co-primary endpoint of a significant improvement in median overall survival (mOS) in the ITT population in the interim analysis. The mOS in the PD-L1 IC-positive study population failed therefore not formally tested.

a Stratified. b Cannot be formally determined based on the pre-specified hierarchical analysis plan.

1L = 1st line therapy; 2L = 2nd line therapy; A = Atezolizumab; Bev = Bevacizumab; Carbo = Carboplatin; CI = Confidence interval; Cis = Cisplatin; Doc = Docetaxel; E = Etoposide; ES-SCLC = "Extensive-stage" small cell lung cancer; Gem = Gemcitabine; HCC = Hepatocellular carcinoma; HR = Hazard ratio; IC = Tumor infiltrating immune cell; ITT = Intention-to-treat; NE = Not reached; NSCLC = Non-small cell lung cancer; OS = Overall survival; P = Paclitaxel; Pem = Pemetrexed; Plac = Placebo; S = Sorafenib; TC = Tumor cell; TNBC = Triple negative breast cancer; UC = Urothelial carcinoma; Vin = Vinflunin; WT = Wild type.

References

1. Socinski MA et al. N Engl J Med 2018; 378: 2288-2301. 2. Rittmeyer A et al. Lancet 2017; 389: 255-265. 3. Liu SV et al. WCLC 2018; Abstract No. PL02.07. 4. Powles T et al. N Engl J Med 2018; 391: 748-751. 5. Schmid P et al. ASCO 2019; Abstract No. 1003.

PDL1 - Programed Death Ligand 1 NSCLC - Non-small Cell Lung Cancer CIT - Cancer Immunotherapy CIT combo* - Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel EFGR - Epidermal Growth Factor Receptor, TKI - Tyrosine Kinase Inhibitor NCCN - National Comprehensive Cancer Network ES-SCLC - Extensive Stage Small Cell Lung Cancer DOR - Duration of Response mUC, Metastatic Lirothelial Cancer

TNBC - Triple Negative Breast Cancer





Disclaimer:

® = Registered Trade Mark F. Hoffmann - La Roche Limited, Basel, Switzerland. 1. For the use of a Registered Medical Practitioner or a Hospital or a Laboratory only. 2. Full prescribing information available on request. 3. For scientific information on Roche Medicinal Product please write to india.medinfo@roche.com 4. For all Adverse Events/Special Situation Reports with Roche Medicinal Product please report the same to india.drugsafety@roche.com within one business day/24 hours. 5. This promotional input is not valid after 12/05/2022 or any update.

ABRIDGED PRESCRIBING INFORMATION

Atezolizumab Injection (Tecentrig[®])

Composition: Active ingredient: Atezolizumab. Tecentriq is supplied as a single-use vial containing preservative-free, colorless to slightly yellow solution, at an active ingredient concentration of 60 mg/mL as follows: • 14 mL vial containing a total of 840 mg atezolizumab • 20 mL vial containing a total of 1,200 mg atezolizumab. Indications: Urothelial carcinoma: Tecentriq is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma after prior chemotherapy or who are considered cisplatin ineligible. Non-small cell lung cancer: Tecentriq is also indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. Tecentriq in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies. Small cell lung cancer. Tecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). Triple-negative breast cancer: Tecentriq, in combination with nab-paclitaxel, is indicated for the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors have PD-L1 expression >1%, and who have not received prior chemotherapy for metastatic disease. Dosage and administration: Tecentriq must be administered as an intravenous infusion under the supervision of a qualified healthcare professional. Do not administer as an IV push or bolus. The initial dose of Tecentriq must be administered over 60 minutes. If the first infusion is tolerated all subsequent infusions may be administered over 30 minutes. Tecentriq monotherapy 2L NSCLC, 1L/2L UC. The recommended dose of Tecentriq is in monotherapy or combination therapy: • 840 mg administered by IV infusion every 3 weeks, or • 1200 mg administered by IV infusion every 3 weeks Tecentriq combination therapy 1L non-squamous NSCLC: Tecentriq in combination with bevacizumab, paclitaxel, and carboplatin During the induction phase, Tecentriq is administered according to its dosing schedules by intravenous (IV) infusion and bevacizumab, paclitaxel and carboplatin are administered every 3 weeks for four or six cycles. The induction phase is followed by a maintenance phase without chemotherapy in which Tecentriq is administered according to its dosing schedules by IV infusion and bevacizumab is administered every 3 weeks. 1L ES-SCLC: Tecentriq in combination with carboplatin and etoposide During the induction phase, Tecentriq is administered according to its dosing schedules by IV infusion and carboplatin and etoposide are administered by IV infusion every three weeks for four cycles.. Carboplatin and etoposide are administered on day 1 of each cycle, and etoposide is also administered on days 2 and 3. The induction phase is followed by a maintenance phase without chemotherapy in which Tecentriq is administered according to its dosing schedules by IV infusion, 1L TNBC: Tecentriq in combination with nab-paclitaxel The recommended dose of Tecentriq is 840 mg administered by IV infusion, followed by 100 mg/m2 nab-paclitaxel. For each 28-day cycle Tecentriq is administered on days 1 and 15, and nab-paclitaxel is administered on days 1, 8 and 15. Duration of Treatment: Patients are treated with Tecentriq until loss of clinical benefit or unacceptable toxicity. 1L TNBC Delayed or Missed Doses: If a planned dose of Tecentriq is missed, it should be administered as soon as possible; do not wait until the next planned dose. The schedule of administration should be adjusted to maintain the appropriate interval between doses. Dose Modifications: No dose reductions of Tecentriq are recommended. Pediatric use: The safety and efficacy of Tecentriq in children and adolescents below 18 years of age have not been established. Contraindications: Tecentriq is contraindicated in patients with a known hypersensitivity to atezolizumab or any of the excipients. Warnings and Precautions: Immune-related pneumonitis: Cases of pneumonitis, including fatal cases, have been observed in clinical trials with Tecentriq. Treatment with Tecentriq should be withheld for Grade 2 pneumonitis, and treatment with corticosteroid therapy (1-2 mg/kg/day prednisone or equivalent) should be initiated. Treatment with Tecentriq may be resumed in patients with complete or partial resolution (Grade 0 to 1) within 12 weeks, and after corticosteroids have been reduced to <10 mg/day oral prednisone or equivalent. Treatment with Tecentriq should be permanently discontinued for Grade 3 or 4 pneumonitis. Immune-related hepatitis: Cases of hepatitis, some leading to fatal outcomes, have been observed in clinical trials with Tecentriq. Treatment with Tecentriq should be withheld for Grade 2 hepatitis and treatment with corticosteroid therapy (1-2 mg/kg/day prednisone or equivalent) should be initiated. Treatment with Tecentrig may be resumed in patients with complete or partial resolution (Grade 0 to 1) within 12 weeks, and after corticosteroids have been reduced to <10 mg/day oral prednisone or equivalent. Treatment with Tecentriq should be permanently discontinued for Grade 3 or Grade 4 events. Immune-related colitis: Cases of diarrhea or colitis have been observed in clinical trials with Tecentriq. Treatment with Tecentriq should be withheld for Grade 2 or 3 diarrhea. For Grade 2 diarrhea or colitis, treatment with corticosteroid therapy (1-2 mg/kg/day prednisone or equivalent) should be initiated. Treatment with Tecentriq may be resumed in patients with complete or partial resolution (Grade 0 to 1) within 12 weeks, and after corticosteroids have been reduced to <10 mg/day oral prednisone or equivalent. Treat Grade 3 diarrhea or colitis, initiate IV corticosteroids as in Grade 2, and convert to oral corticosteroids after improvement. Treatment with Tecentriq should be permanently discontinued for Grade 4 diarrhea or colitis. Immune-related endocrinopathies: Hypothyroidism, hyperthyroidism, adrenal insufficiency and type 1 diabetes mellitus, including diabetic ketoacidosis, have been observed in clinical trials with Tecentriq. For symptomatic hypothyroidism, Tecentriq should be withheld and Treatment with Tecentriq may be resumed when symptoms are controlled and the patient is clinically stable. Treatment with thyroid hormone replacement should be initiated as needed. For symptomatic hyperthyroidism, Tecentriq should be withheld and Treatment with Tecentriq may be resumed when symptoms are controlled and the patient is clinically stable. Treatment with anti-thyroid therapy should be initiated as needed. For symptomatic adrenal insufficiency, Tecentriq should be withheld and Treatment with corticosteroid therapy (1-2 mg/kg/day prednisone or equivalent) should be initiated. Treatment with Tecentriq may be resumed in patients with complete or partial resolution (Grade 0 to 1) within 12 weeks, and after corticosteroids have been reduced to <10 mg/day oral prednisone or equivalent. Treatment with Tecentriq should be withheld for Grade 2 or Grade 3 hypophysitis and Treatment with corticosteroid therapy (1-2 mg/kg/day prednisone or equivalent) should be initiated. Treatment with Tecentriq may be resumed in patients with complete or partial resolution (Grade 0 to 1) within 12 weeks, and after corticosteroids have been reduced to <10 mg/day oral prednisone or equivalent. For Grade 4 Hypophysitis, treatment with Tecentriq should be permanently discontinued. Tecentriq should be withheld and Treatment with insulin should be initiated for type 1 diabetes mellitus in case of ≥ Grade 3 hyperglycemia (fasting glucose >250 mg/dL), Treatment with Tecentriq may be resumed when symptoms are controlled and the patient is clinically stable. Immune-related meningoencephalitis and neuropathies: Meningoencephalitis has been observed in clinical trials with Tecentriq. Patients should be monitored for clinical signs and symptoms of meningitis or encephalitis. Myasthenic syndrome/myasthenia gravis or Guillain-Barré syndrome, which may be life threatening, were observed in patients receiving Tecentriq. Patients should be monitored for symptoms of motor and sensory neuropathy. Treatment with Tecentriq should be permanently discontinued for all grades of Meningitis, encephalitis, myasthenic syndrome /myasthenia gravis, Guillain-Barré syndrome. Immune-related pancreatitis: Pancreatitis, including increases in serum amylase and lipase levels, has been observed in clinical trials with Tecentriq. Patients should be closely monitored for signs and symptoms that are suggestive of acute pancreatitis. Treatment with Tecentriq should be withheld for Grade 2 or 3 pancreatitis (> Grade 3 serum amylase or lipase levels increased [>2.0 ULN]). Treatment with corticosteroid therapy (1-2 mg/kg/day prednisone or equivalent) should be initiated. Treatment with Tecentriq may be resumed in patients with complete or partial resolution (Grade 0 to 1) within 12 weeks, and after corticosteroids have been reduced to ≤10 mg/day oral prednisone or equivalent. Treatment with Tecentriq should be permanently discontinued for Grade 4, or any grade of recurrent pancreatitis. Immune-related myocarditis: has been observed in clinical trials with Tecentriq. Tecentriq should be withheld for Grade 2 or Grade 3 or 4 myocarditis. Immune-related myositis: Treatment with Tecentriq should be withheld for Grade 2 or Grade 3 myositis and treatment with corticosteroid therapy (1-2 mg/kg/day prednisone or equivalent) should be initiated. Treatment with Tecentriq may be resumed in patients with complete or partial resolution (Grade 0 to 1) within 12 weeks, and after corticosteroids have been reduced to <10 mg/day oral prednisone or equivalent. Treatment with Tecentriq should be permanently discontinued for Grade 3 recurrent myositis or Grade 4 events. Immune-related nephritis: Nephritis has been observed in clinical trials with Tecentriq. For grade 2 nephritis, Tecentriq should be withheld and treatment with corticosteroid therapy (1-2 mg/kg/day prednisone or equivalent) should be initiated. Treatment with Tecentriq may be resumed in patients with complete or partial resolution (Grade 0 to 1) within 12 weeks, and after corticosteroids have been reduced to <10 mg/day oral prednisone or equivalent. Treatment with Tecentriq should be permanently discontinued for Grade 3 or 4 nephritis. Infusion related reactions: Infusion related reactions (IRRs) have been observed in clinical trials with Tecentriq. For, Grade 1 or 2 infusion related reactions, the rate of infusion should be reduced or treatment should be withheld and premedication with antipyretic and antihistamines may be considered for subsequent doses. Tecentriq should be permanently discontinued in patients with Grade 3 or 4 infusion related reactions. Rash: For Grade 3 rash, the treatment with Tecentriq should be withheld. For Grade 4, the Tecentriq should be permanently discontinued. Special populations: Patients with autoimmune disease were excluded from clinical trials with Tecentriq. In the absence of data, Tecentriq should be used with caution in patients with autoimmune disease, after assessment of the potential risk-benefit. Embryofetal toxicity: Based on the mechanism of action, the use of Tecentriq may cause fetal harm. Animal studies have demonstrated that inhibition of the PD-L1/PD-1 pathway can lead to increased risk of immune-related rejection of the developing fetus resulting in fetal death. Pregnant women should be advised of the potential risk to the fetus. Women of childbearing potential should be advised to use highly effective contraception during treatment with Tecentriq and for 5 months after the last dose. General Disorders: Peripheral Edema of all grades is very common adverse drug reaction when Tecentriq is used as a part of combination therapy treatment. Use in Special population: Fertility: Based on animal studies, Tecentriq may impair fertility in females of reproductive potential while receiving treatment. **Contraception:** Female patients of childbearing potential should use highly effective contraception and take active measures to avoid pregnancy while undergoing Tecentriq treatment and for at least 5 months after the last dose. **Pregnancy:** There are no clinical studies of Tecentriq in pregnant women. Tecentriq is not recommended during pregnancy unless the potential benefit for the mother outweighs the potential risk to the fetus. Labor and Delivery: The use of Tecentriq during labor and delivery has not been established. Lactation: It is not known whether Tecentriq is excreted in human breast milk. No studies have been conducted to assess the impact of Tecentriq on milk production or its presence in breast milk. As the potential for harm to the nursing infant is unknown, a decision must be made to either discontinue breast-feeding or discontinue Tecentriq therapy. Pediatric use: Tecentriq is not approved for use in patients under the age of 18 years. The safety and efficacy of Tecentriq in this population has not been established. Tecentriq did not demonstrate clinical benefit in pediatric patients in a clinical trial. Geriatric use: No overall differences in safety or efficacy were observed between patients \geq 65 years of age and younger patients. Side Effects: The most commonly reported AEs with Tecentriq in monotherapy includes fatigue, decreased appetite, cough, nausea, dyspnea, constipation, diarrhea, pyrexia, vomiting, arthralgia, back pain, urinary tract infection, asthenia, anemia, pruritus, rash, headache, and in case of combination therapy it includes anemia, neutropenia, thrombocytopenia, leukopenia, hypothyroidism, constipation, headache, lung infection, hypomagnesemia, dizziness, peripheral neuropathy, alopecia, hypertension. Post marketing – No new adverse drug reactions have been identified from postmarketing experience. Storage: Vials: - Store in a refrigerator at 2°C - 8°C. Keep vial in the outer carton in order to protect from light. DO NOT FREEZE. DO NOT SHAKE. This medicine should not be used after the Expiry Date shown on the pack. The diluted solution for infusion should be used immediately. If the solution is not used immediately, it can be stored for up to 30 days at 2°C 8°C, or 24 hours at ambient temperature (\leq 25°C) if prepared under aseptic conditions. **DESCRIPTION:** Atezolizumab is a programmed cell death ligand 1 (PD-L1) blocking antibody. Atezolizumab is an Fc-engineered, humanized, non-glycosylated IgG1 kappa immunoglobulin that has a calculated molecular mass of 145 kDa. Shelf-life: 3 Years for Atezolizumab Injection 1200mg/20ml and 2 Years for Atezolizumab Injection 840mg/14ml Packs: Each pack contains: • A single-use vial of 20ml containing 1200mg of atezolizumab (60mg/ml). • A single-use vial of 14ml containing 840mg of atezolizumab (60mg/ml) Please read full prescribing information before usage

DETAILS OF PERMISSION OR LICENSE NUMBER WITH DATE IMP-063/2017 Dated 31 March 2017

DATE OF REVISION Current at April 2020, Version13.0 PM-IN-0560

KE TRUDA[®] (pembrolizumab) Injection 100 mg **KEYNOTE-024:** 5-year OS Analysis^{a,1}

KEYTRUDA[®] approximately **Doubles 5-Years OS** rate despite of 66% effective crossover rate^a



References:

Adapted from: Brahmer JR et al. KEYNOTE-024 5-Year OS Update: First-line Pembrolizumab vs Platinum-Based Chemotherapy in Patients with Metastatic Non-Small-Cell Lung Cancer and PD-L1 Tumor Proportion Score ≥ 50%. Presented at ESMO 2020

2. Adopted on 25/11/2019 from KEYNOTE 024 3 year survival update: Pembrolizumab Versus Platinum Based Chemotherapy for Advanced NSCLC; Reck KN024 WCLC 2019.

OS: Overall Survival; HR: Hazard Ratio; CI: Confidence Interval; mo: Months; PFS: Progression-Free Survival; ORR: Overall Response Rate; DoR: Duration of Response; RECIST: Response Evaluation Criteria in Solid Tumors; ECOG: Eastern Cooperative Oncology Group

Study Design Brahmer et al 2020

KEYNOTE-024 was a 5-year follow-up study. Eligible patients were randomized to receive Pembrolizumab (KEYTRUDA*) (200 mg Q3W for up to 35 cycles [~2 years]) or chemotherapy. Randomization was stratified by ECOG PS (0/1), histology (squamous/nonsquamous), and region (East Asia/other). For second-course, patients were randomized to receive Pembrolizumab (KEYTRUDA*) (200 mg Q3W for up to 17 cycles [1 year] in patients who completed 2 years of therapy or who stopped Pembrolizumab (KEYTRUDA*) after achieving CR and then had PD were eligible for a second course of Pembrolizumab (KEYTRUDA*) monotherapy. Patients were randomized to receive chemotherapy who had PD and met eligibility criteria could cross over to Pembrolizumab (KEYTRUDA*) monotherapy. Endpoints included PFS (primary); OS, ORR, and safety (secondary); and DoR (exploratory). For this analysis, response/PD was assessed by investigators per RECIST v1.1.

KEYNOTE-024 3-Year Survival Update

Patients were randomized to Pembrolizumab (KEYTRUDA*) 200 mg for 2 years or platinum doublet 4- to 6- cycles plus optional maintenance (nonsquamous), with stratification by ECOG score of 0 or 1, tumor histology (squamous/nonsquamous), and region (East Asia/non-East Asia). Patients in the chemotherapy arm could cross over to Pembrolizumab (KEYTRUDA') upon disease progression if they met eligibility criteria. PFS was the primary endpoint and OS was key secondary endpoint.

° ITT population. ^b Effective crossover rate from chemotherapy to anti-PD-(L)1 therapy, 66.0% (99 patients in total crossed over to anti-PD-[L]1 therapy: 83 patients crossed over to pembrolizumab during the study, and 16 patients received subsequent anti-PD-[L]1 therapy outside of crossover, patients may have received > 1 subsequent anti-PD-[L]1 therapy). Data cutoff; June 1, 2020.



Abridged Prescribing Information KEYTRUDA®

[Pembrolizumab 100 mg/4 mL (25 mg/mL) Injection]

INDICATIONS: KEYTTÜLDA⁴ (perinducturula) is indicated. For the treatment of patients with unreascatable or metastatic melacoma; 4 A montherapy for the first-line treatment of metastatic melacoma; 4 A montherapy for the testiment of locally advanced or metastatic NECCI in adults whose turnous express PD-1 with a 15%. TIPE of and who have necessed a local cosponse trunture advanced or metastatic NECCI in adults whose turnous appress PD-1 with a 15%. TIPE of and who have necessed a local cosponse provide metastatic NECCI in adults whose turnous appress PD-1 with a 15%. TIPE of the testiment of Non-Times experiment of the testiment of Non-Times experiment of the testiment of Non-Times experiment. Patients and Non-Times PD are subject to the testiment of Non-Times experiment experiment of Non-Times experiment experiment of Non-Times experiment experimate exp

AE Reporting

Greeting from MSD Pharmaceuticals, Pvt Ltd To report Adverse Events (AEs) related to our products, please contact :

Mode of reporting the adverse event	Details
Fax	0124-4375562
Toll Free Number	18001032642
E-mail	pharmacovigilance.india@merck.com
Postal Address	Global Pharmacovigilance Department, MSD Pharmaceuticals Pvt. Ltd., 6th Floor, Vatika Towers-B, Sector-54, Gurgaon- 122002.

Adverse Event (AE): Per the International Conference on Harmonization (ICH), an adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this product. Privacy Note: Any personal data provided by you will be treated by MSD with full respect of your privacy. Please read more about MSD's privacy commitment at www.merck.com/privacy/. In case you want to delete or edit Personal Health Information (PHI) already collected by MSD India please request at by MSD Pharmacovigilance.india@merck.com or call at 1244652637"

Global Pharmacovigilance, MSD Pharmaceuticals Pvt Ltd.

Before prescribing KEYTRUDA[®], please read the full Prescribing Information For the use only of registered medical practitioners



Copyright © 2020 MSD Pharmaceuticals Pvt. Ltd., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. All rights reserved. MSD Pharmaceuticals Pvt. Ltd.

MSD Pharmaceuticals Pvt. Ltd. Platina, 10th Floor, C-59, G-Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400098, Tel.No: 022-67898888 www.msdindia.com



IN-KEY-00321 - 21/10/2020 - 14/10/2021



For patients with recurrent or metastatic SCCHN after platinum-based therapy,

START EARLY with OPDYTA®


as your preferred monotherapy post-platinum

OPDY

(nivolumab)

IN THE LAD OR R/M SETTING^{#1}:

If your patient receives a **platinumbased therapy**[†] and progresses...



LAD: Locally Advanced Disease; R/M SCCHN: Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck # Based on Checkmate 141 eligibility criteria.

† Therapy administered in the following treatment settings: locally advanced disease (LAD)

(neoadjuvant/induction, adjuvant, and primary [unresectable locally advanced] settings) and de novo metastatic. 1. Gillison ML, Blumenschein G Jr, Fayette J, et al. CheckMate 141: 1-year update and subgroup analysis of nivolumab as first-line therapy in patients with recurrent/metastatic head and neck cancer. Oncologist. 2018;23(9):1079-1082. 2. Opdyta Prescribing Information Version 6.3 dated 23-Apr-2019.





Give MORE patients the OPDYTA® opportunity!

NOW

APPROVED IN

Ref. 2. Opdyta Prescribing Information Version 6.3 dated 23-Apr-2019.
Abridged Prescribing Information (API)
For the use of an oncologist or a hospital or a laboratory only. OPDYTA® 10 mg/mL concentrate for solution for infusion. Composition: One vial of 4 mL contains 40 mg of nivolumab. One vial of 10 mL contains 100 mg of nivolumab.
Indications: NSCLC: As a single agent for the treatment of locally advanced or metastatic squamous cell carcinoma of the head and head after platinum-based herapy; Melanoma: As a single agent for the treatment of patients with BRAF V600 wildtype unresectable or metastatic melanoma, For the treatment of patients with BRAF V600 wildtype unresectable or metastatic melanoma. For the treatment of patients with patients with BRAF V600 wildtype unresectable or metastatic melanoma. For the treatment of patients with patients with patient or patients with metastatic dassea by hoging windtype unresectable or metastatic dassea by operassion with patients with hepidatoxin containing chemotherapy. Colorectal Cancer (CRG) As monoherapy for the treatment of patients with patients with explore the patient with a herapy with hoging patient with a patient explore the patient with a patient

ullı Bristol Myers Squibb[™]

Bristol-Myers Squibb India Private Limited 6th floor, Tower 1, One International Centre, Senapati Bapat Marg, Elphinstone (W), Mumbai - 400 013, India. **INDICATIONS²**



BECOME I-OSI MEMBER

www.immunooncologyindia.com/join-iosi

Click on below link to watch conference

www.immunooncologyindia.com/iosi

VIRTUAL CONGRESS MANAGED BY

rive coute Digital Events

Nimesh Bafna

Conference Manager, 2nd I-OSI Congress 2020 Director, River Route Event, Mumbai Mobile: +91 9821079650 | E-mail : bafnanimesh@gmail.com

RIVER ROUTE Creative Group, LLP Unit No. 9, Cama Industrial Premises Co-Op Society Ltd., Sunmil Compound, Lower Parel (W), Mumbai - 400 013